ライフサイエンスコーパス: fetuin

1 ages, or whole glycosylated proteins such as fetuin.

2 as precipitation occurred in minutes without fetuin.

3 exhibited markedly reduced binding of BOB93/fetuin.

4 tion of complexes of calcium, phosphate, and fetuin.

5 litated by the negative acute-phase protein, fetuin.

6 e identified from a trypsin digest of bovine fetuin.

7 sialylated biantennary N-glycan derived from fetuin.

8 Human fetuin A (HFA) plays a prominent pathophysiological role

9 IA) was developed for the detection of human fetuin A (HFA), a specific biomarker for hepatocellular

10 (IVD) procedure has been developed for human fetuin A (HFA), an important disease biomarker for infla

11 based on monitoring the interactions between fetuin A and NA enzyme.

12 These studies identify fetuin A as a potential extracellular regulator of m-cal

13 n also co-localized with fluorescein-labeled fetuin A at the wound site.

14 the site-specific modification of endogenous fetuin A in human plasma, the synthesis of tandem fluoro

15 Fetuin A increased resealing of scrape-damaged wild-type

16 ar protein kinase C theta activity and serum fetuin A levels.

17 onsistent with the yeast two-hybrid studies, fetuin A neither stabilized mu-calpain nor prevented its

18 The effect of fetuin A on calpain-mediated plasma membrane resealing w

19 Bovine fetuin A stabilized proteolytic activity of purified m-c

20 alpha(2)-Heremans-Schmid glycoprotein (human fetuin A) as a binding partner for calpain domain III (D

21 ast growth factor 23, osteoprotegerin (OPG), fetuin A, and clinical and biochemical parameters.

22 on and the only macromolecule in solution is fetuin, a 48-kDa inhibitor of apatite growth.

23 ent on the presence of the sialoglycoprotein fetuin, a constituent of bovine serum.

24 Fetuin, a negative acute-phase protein, recently was imp

25 rrelated with a 65 to 75% reduction in serum fetuin, a reduction that appears to be caused by the cle

26 Our studies demonstrate that fetuin, a serum glycoprotein that is abundant in the fet

27 core (beta = -0.05, p = 0.0293) but not with fetuin-A (beta = 0.04, p = 0.17).

28 ent analyses were done to define the role of fetuin-A (Fet) in mammary tumorigenesis using the polyom

29 betic patients showed significantly elevated fetuin-A (FetA) levels in respect to their controls; par

30 Functional studies of Fetuin-A (FetA) were conducted by using gene silencing i

31 Plasma fetuin-A (g/l +/- SD) was highest in women using oral es

32 % versus -13.6% versus 9.1%) and increase of fetuin-a (P<0.01).

33 ee consumption was inversely associated with fetuin-A (P-trend = 0.06) and CRP in women and gamma-glu

34 ated on a mineral-rich diet, suggesting that fetuin-A acts to inhibit calcification systemically.

35 Serum fetuin-A also influenced the growth of LLC cells injecte

36 an interorgan communication orchestrated by fetuin-A and adiponectin.

37 significant association was observed between fetuin-A and aortic stenosis (adjusted odds ratio, 1.49;

38 nverse association also was observed between fetuin-A and aortic stenosis among participants without

39 Serum fetuin-A and computed tomography-determined liver fat co

40 ether the association between high levels of fetuin-A and diabetes can be attributed to nonalcoholic

41 nsulin action in animal studies, but data on fetuin-A and diabetes risk in humans are sparse and the

42 s with microRNA and calcification inhibitors fetuin-A and matrix Gla protein suggests a novel role fo

43 anti-mineralization capacity due to reduced fetuin-A and matrix gla-protein (MGP) levels.

44 sease, we observed an inverse association of fetuin-A and mitral annular calcification.

45 The tumor cells adhered to immobilized fetuin-A and not alpha(2)-macroglobulin, its major conta

46 w levels of the calcium-regulating proteins, fetuin-A and osteopontin, have been found in the serum o

47 Interestingly, the tumor cells also took up fetuin-A and secreted it back to the medium using an unk

48 valuated the association between human serum fetuin-A and the metabolic syndrome (MetS) in a cohort o

49 Importantly, anti-fetuin-A antibodies inhibited invasion of hepatocytes by

50 carboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibi

51 These studies support the role of fetuin-A as a major growth promoter in serum that can in

52 mmation, intestinal permeability, and plasma fetuin-A as potential mechanistic links between fructose

53 vidence that the uptake of the serum protein fetuin-A by VSMC is a key event in the inhibition of ves

54 increased coronary artery calcification and fetuin-A can inhibit mineralization of vascular smooth m

55 stochemistry demonstrated that serum-derived fetuin-A co-localized with calcified human vascular smoo

56 ssion construct containing full-length mouse fetuin-A complementary DNA (cDNA), linked to a His-tag,

57 Lower serum fetuin-A concentrations are associated with valvular cal

58 Higher human fetuin-A concentrations are strongly associated with Met

59 e nucleotide polymorphisms (SNPs) related to fetuin-A concentrations by a genome-wide association stu

60 ations of the genetic determinants of plasma fetuin-A concentrations have not been conducted.

61 Mean fetuin-A concentrations were 0.47 +/- 0.10 g/L.

62 Fibroblast growth factor 23, ucMGP, and fetuin-A concentrations were measured at baseline.

63 We evaluated the associations among serum fetuin-A concentrations, mitral annular calcification, a

64 t prevalent clinical CVD, we measured plasma fetuin-A concentrations.

65 Participants were categorized by tertiles of fetuin-A concentrations.

66 divided participants into quartiles by serum fetuin-A concentrations.

67 In addition, fetuin-A enhanced phagocytosis of vesicles by VSMC.

68 Mice that lack fetuin-A exhibit extensive soft tissue calcification, wh

69 and bone metastasis samples displayed robust fetuin-A expression, and we demonstrated serum immune re

70 pants (80 of 177) in the highest quartile of fetuin-A had MetS compared with 24% of participants (42

71 th, we showed that LLC tumor cells adhere to fetuin-A in a Ca(2+)-dependent fashion, resulting in gro

72 olonization responded to the levels of serum fetuin-A in a dose-dependent manner, as observed by the

73 tested the hypothesis that overexpression of fetuin-A in Abcc6(-/-) mice counteracts the ectopic mine

74 ctor in circulation, and the serum levels of fetuin-A in patients with PXE as well as in a mouse mode

75 In conclusion, levels of fetuin-A in plasma are strongly associated with SNPs in

76 to our knowledge the first study implicating fetuin-A in prostate cancer and indicating that autoanti

77 together, our data show the significance of fetuin-A in tumor cell growth mechanisms in vitro and op

78 The presence of fetuin-A in vesicles abrogated their ability to nucleate

79 The liver-secreted protein fetuin-A induces peripheral insulin resistance in vitro.

80 To examine the mechanism by which fetuin-A influences LLC colonization and growth, we show

81 Fetuin-A inhibited in vitro VSMC calcification, induced

82 Fetuin-A interferes with insulin action in animal studie

83 However, the processes of fetuin-A intracellular trafficking and MV biogenesis are

84 However, fetuin-A inverted these benign effects of RSFC from an a

85 Fetuin-A is a circulating inhibitor of calcium depositio

86 Fetuin-A is a hepatic secretory protein and a novel risk

87 Fetuin-A is a hepatic secretory protein that binds the i

88 Fetuin-A is a hepatic secretory protein that inhibits ar

89 Fetuin-A is a liver-derived plasma protein involved in t

90 Fetuin-A is a multifunctional hepatic secretory protein

91 Fetuin-A is a multifunctional hepatic secretory protein

92 n cell culture model systems have shown that fetuin-A is a powerful anti-mineralization factor in cir

93 Fetuin-A is a serum glycoprotein in the cystatin family

94 Whereas fetuin-A is an established tumor antigen in several type

95 Higher fetuin-A is associated with incident diabetes mellitus i

96 Among well-functioning older persons, serum fetuin-A is associated with incident diabetes, independe

97 Plasma fetuin-A is associated with type 2 diabetes, and AHSG, t

98 Whether fetuin-A is associated with valvular calcification in ot

99 Biochemical studies showed that fetuin-A is essential for the formation of protein-miner

100 models with follow-up through 2012, a higher fetuin-A level was associated with a higher risk of diab

101 d with a 0.06 g/l ( approximately 13%) lower fetuin-A level.

102 1,025 women (median age = 73 years) who had fetuin-A levels and CVD risk factors evaluated in 1992 t

103 sitive association was observed between high fetuin-A levels and diabetes risk: the relative risk (95

104 Lower fetuin-A levels are associated with arterial calcificati

105 Lower fetuin-A levels are independently associated with greate

106 se-cohort study, we retrospectively measured fetuin-A levels in baseline serum among 406 randomly sel

107 ggest that in the presence of NAFLD elevated fetuin-A levels may impair renal function by RSF-induced

108 Low fetuin-A levels predicted greater risk for CVD mortality

109 tive risk (95% CI) comparing high versus low fetuin-A levels was 1.69 (1.39-2.05) (P for heterogeneit

110 In a pilot study, we observed that higher fetuin-A levels were associated with diabetes mellitus i

111 or cross-sectional studies in humans, higher fetuin-A levels were associated with insulin resistance.

112 Lower fetuin-A levels were associated with older age, but with

113 These findings suggest that plasma fetuin-A levels were independently associated with highe

114 Fetuin-A levels were inversely associated with CAC sever

115 We examined the association of fetuin-A levels with approximately 2.5 million genotyped

116 s to evaluate the prospective association of fetuin-A levels with cardiovascular disease (CVD) mortal

117 Participants with fetuin-A levels within the highest tertile (> 0.97 g/L)

118 iant alone explained 14% of the variation in fetuin-A levels.

119 s many colonies in mice heterozygous for the fetuin-A locus compared with homozygous WT mice and rest

120 vo study we hypothesized that the hepatokine fetuin-A may impair renal function in non alcoholic fatt

121 at maintaining normal circulating levels of fetuin-A may prove beneficial in patients with ESRD.

122 Fetuin-A may provide novel insight into mechanisms leadi

123 Fetuin-A may represent an important inhibitor of dystrop

124 If confirmed, fetuin-A might mark calcium deposition within the vascul

125 ecting Lewis lung carcinoma (LLC) cells into fetuin-A null and their wild-type (WT) littermate contro

126 o the lungs within 2 weeks in the WT but not fetuin-A null mice.

127 metastatic nodules, whereas the lungs of the fetuin-A null mutant mice were virtually free of colonie

128 extracellular region of TRAP interacts with fetuin-A on hepatocyte membranes and that this interacti

129 Future studies should evaluate whether fetuin-A predicts coronary artery disease risk.

130 ratio for CVD mortality comparing the lowest fetuin-A quartile with all higher values was 1.76 (95% c

131 Higher fetuin-A quartiles were also strongly and independently

132 e odds ratio (OR) (95% CI) comparing extreme fetuin-A quintiles was 1.81 (1.07-3.06) (P for trend = 0

133 indicating that autoantibodies specific for fetuin-A show utility as a prognostic indicator for pros

134 g participants without diabetes, the highest fetuin-A tertile had a significantly lower odds of aorti

135 Those within the highest fetuin-A tertile had significantly lower odds of mitral

136 lonization by the administration of purified fetuin-A to fetuin-A-null mice.

137 Addition of fetuin-A to the culture system prevented the mineralizat

138 The attachment of tumor cells to fetuin-A was accompanied by phosphatidylinositol 3-kinas

139 Each 0.10-g/L (SD)-greater fetuin-A was associated with 19 higher risk of diabetes

140 ordinal logistic regression, each SD higher fetuin-A was associated with 31% lower odds of CAC sever

141 The interaction of cells with fetuin-A was driven mainly by Ca(2+) ions, and cells gro

142 were expressed locally in vibrissae, whereas fetuin-A was expressed highly in the liver.

143 Alexa488-labeled fetuin-A was internalized by human VSMCs, trafficked via

144 tron microscopy-immunogold demonstrated that fetuin-A was internalized by VSMC and concentrated in in

145 f age without diabetes mellitus at baseline, fetuin-A was measured in serum collected in 1992 to 1993

146 In contrast, no association of fetuin-A was observed with PAD or high common or interna

147 Subsequently, fetuin-A was secreted via vesicle release from apoptotic

148 (ALT), aspartate aminotransferase (AST) and fetuin-A were determined in fasting blood samples and th

149 Levels of fetuin-A were slightly decreased in Abcc6-/- serum, and

150 In contrast, the association of fetuin-A with aortic stenosis was modified by the presen

151 d we demonstrated serum immune reactivity to fetuin-A with concomitant development of metastatic cast

152 The association of fetuin-A with CVD mortality differed by diabetes status

153 bserved a particularly strong association of fetuin-A with diabetes risk in women that could not be e

154 We sought to confirm the association of fetuin-A with incident diabetes mellitus in older person

155 gression models evaluated the association of fetuin-A with incident diabetes mellitus.

156 However, the longitudinal association of fetuin-A with incident type 2 diabetes mellitus is unkno

157 No significant association of fetuin-A with mortality (HR, 0.84 [CI, 0.55 to 1.27]) or

158 is study was to determine the association of fetuin-A with subclinical cardiovascular disease (CVD) i

159 The association of fetuin-A with subclinical CVD in the general population

160 One of them is fetuin-A, a 60-kDa glycoprotein synthesized in the liver

161 Dialysis patients with low levels of serum fetuin-A, a circulating inhibitor of mineralization, hav

162 bound to alpha2-Heremans-Schmid glycoprotein/fetuin-A, a hepatocyte-specific protein associated with

163 form the first nidus for mineralization and fetuin-A, a potent circulating inhibitor of calcificatio

164 ound that both the sera of mice deficient in fetuin-A, a serum protein that inhibits calcification, a

165 ses' Health Study, for whom levels of plasma fetuin-A, alanine transaminase (ALT), and gamma-glutamyl

166 other desaturase-associated biomarkers (CRP, fetuin-A, ALT, and GGT) did not lead to appreciable atte

167 immunostaining for matrix-gla-protein (MGP), fetuin-A, and ankylosis protein (Ank) as well as alkalin

168 ification in body fluids, including albumin, fetuin-A, and apolipoprotein A1.

169 icles containing the serum proteins albumin, fetuin-A, and apolipoprotein A1; the mineralization-asso

170 PAD was measured concurrent with fetuin-A, and CAC and cIMT were measured 4.6 years (mean

171 -molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured

172 ers (reflected by gamma-glutamyltransferase, fetuin-A, and sex hormone-binding globulin), markers of

173 ansferase (GGT), alanine transaminase (ALT), fetuin-A, and the algorithm-based fatty liver index (FLI

174 rum and exosome proteins, including albumin, fetuin-A, apolipoprotein-A1, alkaline phosphatase, TNFR1

175 Schmid glycoprotein, commonly referred to as fetuin-A, are reduced in ESRD, a condition associated wi

176 results suggest that normalization of serum fetuin-A, either through gene therapy approaches or by d

177 type 2 diabetes, and AHSG, the gene encoding fetuin-A, has been identified as a susceptibility locus

178 rough distinct molecular mechanisms, such as fetuin-A, osteopontin, and bone morphogenic protein 7, a

179 d bone osteoclastic activity, and lower free fetuin-A, plasma pyrophosphate, and albumin concentratio

180 To study effects of the crosstalk between fetuin-A, RSF and kidney, human renal sinus fat cells (R

181 In the present analyses, we showed that fetuin-A, whose function in cellular attachment in tissu

182 protein fraction was immunoprecipitated on a fetuin-A-adsorbed protein A column, TRAP bound this liga

183 We could demonstrate that fetuin-A-containing CPPs facilitate the clearance of min

184 In mice, fetuin-A-containing CPPs were rapidly cleared by the ret

185 r, onset of malaria infection was delayed in fetuin-A-deficient mice compared to that in wild-type C5

186 enced the growth of LLC cells injected s.c.: fetuin-A-null mice developed small s.c. tumors only afte

187 y the administration of purified fetuin-A to fetuin-A-null mice.

188 hment was confined to the fractions that had fetuin-A.

189 xtracellular Ca(2+) ions as cells growing in fetuin-A.

190 in-A6, one of the cell surface receptors for fetuin-A.

191 ha, IL-6, IL-12, IL-17, malondialdehyde, and fetuin-a.

192 -Heremans-Schmid glycoprotein, also known as fetuin-A.

193 rying two null alleles for the gene encoding fetuin, Ahsg (B6, 129-Ahsg(tm1Mbl)).

194 model glycoproteins included ribonuclease B, fetuin, alpha(1)-acid glycoprotein, immunoglobulin, and

195 Retrocyclin also bound fetuin, an extensively glycosylated protein, with high a

196 ter etidronate injection, and the FMC is 46% fetuin and 53% mineral by mass.

197 ified HA1 oligomers (but not monomers) bound fetuin and agglutinated red blood cells.

198 well on microtiter wells in the presence of fetuin and divalent ions in a carbohydrate-dependent man

199 wn for phosphorylation analysis using bovine fetuin and glycosylation analysis using bovine ribonucle

200 levels of binding to sialylated moieties on fetuin and GPIbalpha.

201 ne ribonuclease B, human transferrin, bovine fetuin and human alpha1-acid glycoprotein, the correspon

202 ing well-characterized N-glycans from bovine fetuin and IgG from human serum.

203 f calcium phosphate mineral and the proteins fetuin and matrix Gla protein (MGP) that was initially d

204 f calcium phosphate mineral and the proteins fetuin and matrix Gla protein that was initially discove

205 orted calcification inhibitory activities of fetuin and MGP may be related to their ability to form s

206 ilar in domain structure to fetuin and, like fetuin and MGP, contains several residues of phosphoseri

207 se observations suggest that spp24 may, like fetuin and MGP, play a role in inhibiting calcification.

208 f two potential glycoprotein cancer markers, fetuin and prostate-specific antigen (PSA), with 10 min

209 d by first comparing N-glycans isolated from fetuin and serum and was then exploited to analyze the e

210 CdtA-II(Ec) and CdtC-II(Ec) bind immobilized fetuin and thyroglobulin as well as fucose and to a less

211 al of N- but not O-linked carbohydrates from fetuin and thyroglobulin prevents binding of CdtA-II(Ec)

212 Da protein is similar in domain structure to fetuin and, like fetuin and MGP, contains several residu

213 l complex consists of about 18% mineral, 80% fetuin, and 2% matrix Gla protein (MGP) by weight, and t

214 ed proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120.

215 proteins including chicken ovalbumin, bovine fetuin, and horseradish peroxidase (HRP) were digested b

216 Model glycoproteins (bovine RNase B, bovine fetuin, and human IgG) and a complex mixture from human

217 trix gamma-carboxyglutamic acid Gla protein, fetuin, and osteopontin, also contribute to vascular cal

218 the glycoproteins alpha1-acid glycoprotein, fetuin, and ribonuclease B, as well as from glycoprotein

219 ycans derived from alpha1-acid glycoprotein, fetuin, and ribonuclease B.

220 trategies using standard glycoproteins (IgG, fetuin, and RNase B) and featured rapid processing time,

221 tylia mollis is a lectin with high finity to fetuin, and used here to differentiate prostate cancer a

222 Anti-human fetuin antibodies render primary human peripheral blood

223 can be specifically inhibited by anti-human fetuin antibodies.

224 osaccharide mass has been demonstrated using fetuin as a model compound.

225 We successfully used fetuin as a model protein to test the feasibility of thi

226 ptimized our automated protocol using bovine fetuin as a standard glycoprotein, and then assessed the

227 With the use of bovine fetuin as a standard glycoprotein, the incubation time w

228 The assay used bovine fetuin as an internal standard and a two-dimensional sol

229 This role of fetuin as an opsonic participant in macrophage-deactivat

230 Thus, macrophages use fetuin as an opsonin for cationic-deactivating molecules

231 ovine RNase B, human transferrin, and bovine fetuin as models to demonstrate the feasibility of the m

232 on six model glycoproteins (RNase B, avidin, fetuin, asialofetuin, transferrin, and AGP) as well as a

233 Using bovine fetuin (because it contains the sialylated O-glycans mos

234 lycoproteins were analyzed, including bovine fetuin, bovine submaxillary gland mucin, and serum immun

235 ed in Pichia pastoris, hen ovalbumin, bovine fetuin, bovine thyroglobulin, and several invertase prep

236 and GuHCl-induced unfolding of bovine serum fetuin (BSF) has been studied by differential scanning c

237 cells with glycoproteins (thyroglobulin and fetuin), but not simple sugars, blocks surface binding o

238 MC in the 9-24-h interval lowers total serum fetuin by 50%.

239 for a receptor-mediated uptake mechanism for fetuin by cultured human VSMCs.

240 When cell extracts were applied onto a fetuin column, both TF and GroEL bound but not GroES.

241 These observations suggest that the fetuin component of the FMC is derived from fetuin initi

242 etidronate injection does not increase serum fetuin despite the fact that 50% of serum fetuin is asso

243 periments with this system demonstrated that fetuin determines the location of mineral growth; in the

244 Fetuin dose-dependently increases macrophage uptake of C

245 Common O-linked sugar chains found in fetuin, equine chorionic gonadotropin, and glycophorin c

246 c (Galbeta1-4GlcNAc) and TF-antigen, and (3) fetuin (FET), the sialylated glycoform of ASF.

247 is the antigen for BOB93, and that BOB93 and fetuin form a complex in solution that is necessary and

248 clearance of the FMC removes the associated fetuin from circulation.

249 The fetuin gene (AHSG) is located on human chromosome 3q27,

250 Tandem spectra of glycopeptides from fetuin, glycophorin A, ovalbumin and gp120 tryptic diges

251 biomarkers of cancer has studied the role of fetuin glycoprotein on the metastatic disease diagnosis.

252 Experiments with glycosidase-treated fetuin, gp120, and CD4 revealed that both O-linked and N

253 Ribonuclease B, bovine fetuin, human alpha 1-acid glycoprotein, and the diamine

254 The electrode analytical response to fetuin in PBS samples, obtained by square wave voltammet

255 We tested the role of systemic fetuin in tumor cell growth and metastasis by injecting

256 Purified bovine fetuin inhibited the precipitation of mineral for over 1

257 Additionally, asialofetuin, not fetuin, inhibited platelet phagocytosis suggesting the i

258 Fetuin inhibits insulin-induced insulin receptor (IR) au

259 fetuin component of the FMC is derived from fetuin initially in serum and that clearance of the FMC

260 The data suggest that fetuin is a natural modulator of galectin-3 secretion/re

261 Additional experiments showed that fetuin is also able to localize calcification to the int

262 um fetuin despite the fact that 50% of serum fetuin is associated with the FMC, and clearance of the

263 In the present studies, we found that fetuin is necessary for macrophages to respond to CNI-14

264 We demonstrate that fetuin is the antigen for BOB93, and that BOB93 and fetu

265 s, as well as N-linked glycans released from fetuin, is used to demonstrate the utility of the tetrap

266 Fetuin knockout (KO) mice demonstrate increased basal an

267 When fed a high-fat diet, fetuin KO mice are resistant to weight gain, demonstrate

268 Glucose and insulin tolerance tests in fetuin KO mice indicate significantly enhanced glucose c

269 Fetuin KO mice subjected to euglycemic-hyperinsulinemic

270 These data suggest that fetuin may play a significant role in regulating postpra

271 This highly specific complex of fetuin, MGP, and mineral prevents the growth, aggregatio

272 cation of mineral growth; in the presence of fetuin mineral grows exclusively within the fibril, wher

273 nt study was carried out to characterize the fetuin-mineral complex (FMC), a high molecular mass comp

274 th results indicate that serum levels of the fetuin-mineral complex are indeed associated with vitami

275 One possibility is that high levels of the fetuin-mineral complex cause defects in the ability of f

276 found at 24 h to 14 days is identical to the fetuin-mineral complex found in the serum of etidronate-

277 appears to be caused by the clearance of the fetuin-mineral complex from serum.

278 ible association between the presence of the fetuin-mineral complex in serum and vitamin D-induced ar

279 D for 96 h, and that there is no detectable fetuin-mineral complex in the blood of rats in which art

280 The first experiment shows that there is a fetuin-mineral complex in the blood of rats in which ext

281 ative agent, and that the serum level of the fetuin-mineral complex is a marker for the activity of t

282 Another possibility is that the fetuin-mineral complex is the downstream product of a pa

283 the timing of the maximal increase in serum fetuin-mineral complex levels.

284 Large amounts of the fetuin-mineral complex were generated in the first 3 h o

285 vitro is accompanied by the formation of the fetuin-mineral complex, a high molecular mass complex of

286 oligosaccharides, including NCAM N-glycans, fetuin N-glycans, synthetic sialylated N-acetyllactosami

287 I or IV or to the negative control proteins fetuin or bovine serum albumin.

288 ther than basic, showed no binding to either fetuin or GPIbalpha.

289 linked oligosaccharides released from bovine fetuin, polyclonal human serum immunoglobulin G (IgG), a

290 Fetuin purified from the FMC contains 3.3 mol of protein

291 The addition of calcium chloride to fetuin resulted in an increase in peeling, whereas subse

292 Fetuin, shown by mass spectrometry not to contain MGP, w

293 was a biphasic drop in ionic calcium in the fetuin solution, however, from 5 to 3 mM in the first ho

294 4) A large protein (fetuin) that selectively inhibits growth of crystals rem

295 show that the previously reported ability of fetuin to inhibit the precipitation of hydroxyapatite fr

296 eral complex cause defects in the ability of fetuin to prevent the growth of the mineral component, w

297 r (Galbeta1,3GalNAcbeta1,3Galalpha-O-Me) and fetuin triantennary asialoglycopeptide.

298 Fetuin uptake and secretion by proliferating and differe

299 Bovine fetuin was used as a model glycoprotein in this study.

300 to a well characterized glycoprotein bovine fetuin with both N- and O-linked glycans and a highly gl